Overview

Safety Study of Tecadenoson to Treat Atrial Fibrillation

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Assess the tolerability and safety of a rapid bolus of tecadenoson at different dose levels when given alone and in combination with a beta-blocker (esmolol) in patients with atrial fibrillation to control rapid heart rate. Explore the pharmacokinetic and pharmacodynamic effects when given alone and in combination with beta-blocker (esmolol).
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Adenosine
Esmolol
Tecadenoson